semaj83/ctmatch_classification huggingface dataset:
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Major Depressive Disorder Bipolar I Disorder Bipolar II Disorder Bipolar Depression Suicidal Ideation Provision of written informed consent [MDD stream only] Diagnosis of major depressive disorder, currently depressed as determined by DSM-IV diagnostic (confirmed using the MINI) [BD stream only] Diagnosis of bipolar disorder, type I or type II, currently depressed as determined by DSM-IV diagnostic (confirmed using the MINI) Both females and males, aged 18 to 65 years Inpatient status Female patients of childbearing potential must have a negative urine human chorionic gonadotropin (hCG) test at enrolment and must be taking or willing to take some acceptable form of birth control during the course of the study if they are or plan to be sexually active The ability to understand and comply with the requirements of the study and capable of providing informed consent Suffering from suicidal ideation/attempts as evidenced by a score of >0 on either of the SSI or CSSRS or both  Current or past psychotic symptoms Substance or alcohol dependence at enrollment (except dependence in full remission, and except for caffeine or nicotine dependence), as defined by DSM-IV Opiates, amphetamine, barbiturate, cocaine, cannabis, or hallucinogen abuse by DSM-IV within 4 weeks prior to enrollment Any pervasive developmental disorder (according to DSM-IV criteria) Diagnosis of dementia (according to DSM-IV criteria) Known intolerance or hypersensitivity to ketamine or midazolam as judged by the investigator Significant medical condition that would contraindicate the use of ketamine, midazolam or that is untreated and would need urgent attention (as determined by treating physician) Medical conditions that would significantly affect absorption, distribution, metabolism, or excretion of ketamine or midazolam Unstable or inadequately treated medical illness (e.g. congestive heart failure, angina pectoris, hypertension) as judged by the investigator Any clinically significant deviation from the reference range in clinical laboratory test results as judged by the investigator
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-64.0,  Depression Alcoholism Drug Abuse African American English speaking Diagnosis of Bipolar Disorder (BD) Able to provide written informed consent  Cognitive impairments Acutely psychotic Medically unstable History of schizophrenia spectrum disorder History of mood incongruent psychotic symptoms History of primary substance disorder History of primary organic disease and/or dementia
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Healthy Volunteers Male or female study participants, aged above 18 years-old; women cannot be pregnant or breastfeeding Body mass index (BMI) greater than or equal to 19 and less than or equal to 28.75 Kg/m2 Good health conditions or without significant diseases, according to best medical judgement, according to protocol requirements and study evaluations: medical history, blood pressure and heart rate measurements, physical examination, electrocardiogram (ECG) and complementary laboratory tests Ability to understand the nature and objectives of the trial, including risks and adverse events; willingness to cooperate with the researcher and proceed according to all study requirements, which shall be confirmed by Informed Consent Form signature  Known hypersensitivity to the investigational product (Zolpidem) or chemically related compounds; history of serious adverse reactions or hypersensitivity to any drug History or presence of hepatic or gastrointestinal diseases, or other condition that interferes with drug absorption, distribution, excretion or metabolism Chronic therapy with any drugs, except oral contraceptives History of hepatic, kidney, lungs, gastrointestinal, epileptic, hematologic or psychiatric disease; hypotension or hypertension, of any etiology, that requires pharmacological treatment; history of myocardial infarction, angina and/or heart failure Electrocardiographic findings that, at investigator are not recommended for study participation Deviations on screening laboratory results that are considered as clinically relevant by the researcher Smoking Intake of more that 5 cups of coffee or tea per day Unusual food habits, e.g., vegetarians History of drugs and alcohol addiction or excessive alcohol consumption (> 35 g/day)
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  HIV Infections You may be eligible for this study if you Are HIV-positive Are at least 18 years old Have symptoms of AIDS dementia including forgetfulness, loss of concentration, slow mental processing, or a loss of muscle control Have been on stable anti-HIV drug therapy for the past 6 weeks (if you are taking anti-HIV drugs)  You will not be eligible for this study if you Have certain serious medical conditions, such as a mental disorder or an opportunistic (AIDS-related) infection
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Spinal Muscular Atrophy Amyotrophic Lateral Sclerosis Spinobulbar Muscular Atrophy ENTRY --Disease Characteristics-- Men aged 18 and over with motor neuron disease, i.e X-linked spinal and bulbar muscular atrophy (Kennedy's disease) Confirmed by androgen receptor, exon-1 mutation genotype Amyotrophic lateral sclerosis Spinal muscular atrophy Significant muscle weakness on manual muscle testing No prisoners No mental disability
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Dystonia Healthy Healthy volunteers who consented to participate in the study and matched for age, sex, handedness with the group of patients with primary focal hand dystonia Patient with primary focal dystonia from our dystonia patient database who consented to participate in the study. This criterion will be established by the preliminary screening in the Human Motor Control Outpatient Clinic  The following subjects will be excluded Healthy volunteers with cognitive complaints, abnormal neurological exam or history of past neurological disease Dystonia patients with the presence of a second neurological disease or condition; abnormal neurological findings on exam that are not related to primary focal dystonia Subjects with past or present neuropsychiatric illness, head trauma with loss of consciousness, epilepsy, cerebro-vascular disease, migraine, past and present history of alcohol abuse, medical conditions that may alter cerebral structure Subjects with abnormal MRI findings at visual inspection (prominent normal variants such as mega cisterna or cavum septum pellucidum, signs of severe cortical or subcortical atrophy, brain tumors, vascular diseases, trauma or AVMs) Subjects with any metallic objects within them just prior to MR imaging (cardiac or neural pacemaker, aneurysm clips [metal clips on the wall of a large artery], metallic prostheses [including heart valves and cochlear implants] or shrapnel fragments. Welders and metal workers are also at risk for injury and may not take part in the study because of possible small metal fragments in the eye of which they may be unaware Subjects not capable of giving an informed consent Women who are pregnant Children
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 21.0-999.0,  Parkinson Disease We will only PD patients with a stable clinical response to L-DOPA and DAergic agents We will only recruit patients with early or mild-to-moderate PD (score on Hoehn & Yahr scale 148 less than 3) To obtain a homogeneous group, the PD cohort will comprise only non-demented, non-depressed, with parkinsonian symptoms and signs primarily akineto-rigid If resting tremor is present, only patients with mild or moderate tremor (UPDRS tremor ratings 1 or 2 in the right upper limb) will be included in the study Our group of healthy volunteers will the following age range: 21-30 years, 31-40 years, 41-50 years, 51-60 years, 61-70 years, and 70 years and over Research subjects may be male or female and they must be right-handed Pregnant women will not participate in the study Research subjects will be asked to refrain from caffeine and nicotine for at least 12 hours and to abstain from alcohol at least 24 hours before the fMRI  Subjects belonging to one of the following groups will be excluded from the study Subjects with a familial history of PD Patients with a marked resting tremor (score at the UPDRS scale above 3 in the right upper limb) Patients with a score at Hoehn & Yahr scale equal or above 3 Patients with progressive neurological disorders other than PD Subjects with cognitive impairment (i.e., score on Mattis scale below 123/144) Subjects with significant mood disturbances (i.e., score on BDI scale above 10) Subjects with abnormal MRI findings at visual inspection (prominent normal variants such as mega cisterna or cavum septum pellucidum, signs of severe cortical or subcortical atrophy, brain tumors, vascular diseases, trauma or AVMs) Subjects with a history of significant medical disorders, or requiring chronic treatment with other drugs that cannot be stopped Subjects with prior exposure to neuroleptic agents or drug use
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Pick Disease of the Brain -Six patients referred to the Cognitive Neuroscience Section, NINDS, with a clinical diagnosis of FTD confirmed here, will be selected to participate in the study  Greater than 75 years of age Presence of metal in the head other than dental hardware Broken skin in the area of the stimulating electrodes Any behavioral disorder that makes testing impossible Children are excluded, as FTD is not a childhood illness
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 12.0-999.0,  Prion Disease Aged 12 years or more, diagnosed with any type of human prion disease  In a coma, or in a pre-terminal phase of disease such that prolongation of the current quality of life would not be supported Known sensitivity to quinacrine Been taking any other putative anti-prion therapy for less than 8 weeks
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 45.0-999.0,  Menopause Postmenopausal Vaginal Atrophy Postmenopausal women whose last menstruation was at least two years previously
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  B Cell Lymphoma • Patients with one of the following B-cell Lymphoma CD 20 positive : Mantle cell, Marginal zone, lymphocytic, follicular requiring treatment, Histological transformation from low grade to high grade, diffuse large cell without adverse prognostic factors defined by the international prognostic index (IPI) Aged from 18 to 80 years Untreated with chemotherapy except with Chlorambucil or Cyclophosphamide per os alone less than 6 months Previous radiotherapy except if localized Performance status < 3 Signed inform consent  Other type of lymphomas: Burkitt, T cell, CD 20 negative Central nervous system or meningeal involvement Contraindication to any drug contained in the chemotherapy regimen HIV disease, active hepatitis B or C Treatment with polychemotherapy before except with Chlorambucil or Cyclophosphamide per os less than 6 months Prior extended radiotherapy Any serious active disease or co-morbid medical condition (according to investigator's decision ) Renal deficiency (clearance < 30 ml/mn), liver deficiency (bilirubin > 30 mmol/l) unless related to lymphoma Neuropathy> grade 2 within 14 days before enrollment Platelets < 30.109/l within 14 days before enrollment
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Dementia Mild Cognitive Impairment Diagnosis of dementia under the DSM-IV or of Mild Cognitive Impairment, using the Peterson Living in the community (home, apartment or collective housing with nursing care available for less than 40 hours per week) Patient able to provide written informed consent, or provision of written informed consent by a legal guardian/proxy Availability of a caregiver willing to provide consent for required components of the study Fluent in English May be participating in a Phase IV or other post-marketing follow up study of an approved product for treatment of dementia  No concomitant life-threatening illness (a condition which is likely to interfere with the patient's ability to complete the study) Not unwilling or unable to complete the study Not concurrently participating in a clinical trial of an investigational drug (phase I, II or III) Unwillingness of patient or legal guardian / proxy to provide written informed consent Unwillingness of caregiver to provide written informed consent For patients with diagnosis of mild cognitive impairment: current or previous treatment with any cholinesterase or memantine
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 18.0-90.0,  Alzheimer's Disease Mild Cognitive Impairment Healthy for patients with dementia Patients: clinical diagnosis of AD or mild cognitive impairment primary language German  for healthy subjects and patients with dementia/MCI Known allergy to levodopa or tetrazine History of medication/drug abuse Acute nicotine withdrawal or > 15 cigarettes per day > 6 cups/glasses of coffee, caffeine drinks or energy drinks per day > 50 grams of alcohol per day Severe hypertonia (systole >160 mm Hg) Severe arteriosclerosis Diabetes, asthma, or glaucoma Severe hearing disability
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  ALS Cases were eligible to participate in the original study if (1) they had received a diagnosis of ALS within 2 years; (2) they lived in New England at least half the year; (3) they spoke English; (4) they were mentally and physically able to participate. The same were used for controls  Potential controls were excluded if they had a physician diagnosis of a neurodegenerative disease, polio, post-polio syndrome, or nondiabetic neuropathy Pregnant women were excluded from both case and control groups
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Multiple Sclerosis Diagnosis of relapsing remitting or secondary progressive with superimposed relapses MS Age between 18 and 60, inclusive EDSS between 0 and 6.5 Receiving treatment with Interferon beta (either 1a or 1b) at fully tolerated dose for at least 6 months prior to enrollment and with evidence of clinical efficacy (i.e. reduction or absence of clinical relapses) at the time of the enrollment  Clinical relapse at the time of the enrollment or within the previous 3 months Undergoing chronic therapy with any other immunomodulatory or immunosuppressive medication (excluding standard dosages of steroids intravenously/intramuscularly injected and orally taken for the treatment of relapses) besides Interferon within the past 6 months Currently taking medications used for treatment of cognition/fatigue such as Donepezil (Aricept), Modafinil (Provigil), Amantadine, or other drugs that may act as temporary stimulants or depressants for the central nervous system Currently taking other medications used for symptomatic relief that may affect cognition. The study neurologist will make the determination of eligibility Clinically significant medical condition that, in the opinion of the investigator, would compromise patient's safety or affect his/her MRI (e.g., diabetes mellitus, chronic hypertension, severe anemia, kidney disease, heart disease [angina, arrhythmias, congestive heart failure]) Pregnancy or current breastfeeding Previous eye surgery of any kind Inability to provide informed consent. The ability of the patients in understanding all the aspects of the protocol will be judged by the means of a questionnaire Permanent tattooed makeup (eyeliner, lip, etc.) or general tattoos. Subjects with tattoos will be excluded if those are in a dangerous location in the body or made with colors whose content in iron (e.g. dark blue or dark green) cannot be definitely ruled out by the Investigators Any non-organic implant or any other device such as: cardiac pacemaker, insulin infusion pump, implanted drug infusion device, cochlear, otologic, or ear implant, transdermal medication patch (nitro, hormones) that may cause problems if removed, even temporarily, any metallic implants or objects, body piercing(s), bone/joint pin, screw, nail, plate, wire sutures or surgical staples, shunt
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Differentiated Thyroid Carcinoma Hiostologically proved DTC (M0)  Preoperative metastasis